Issue 11 2019

22 CEO MONTHLY / ISSUE 11 2019 , Third Pole Therapeutics Names Bill Athenson New CEO Enhanced executive teampositions inhaled portable nitric oxide company for accelerated growth. Third Pole Therapeutics, a privately held company developing and delivering transformative life-saving cardio-pulmonary therapies, has named seasoned healthcare executive Bill Athenson as its new Chief Executive Officer, the company announced today. David Zapol, Third Pole's founding CEO, will continue providing strategic counsel to Third Pole. Athenson joins Third Pole building on the recent hires of Elizabeth Holmberg as Chief Financial Officer, formerly CFO of Ikaria, and Christopher Miles as Chief Technology Officer, formerly global head of consulting services at Altran. These key enhancements to Third Pole's senior management structure position the company for accelerated growth. "I am delighted to take the helm at Third Pole as the company transitions to its next stage of commercial development," said Bill Athenson, Third Pole's CEO. "Third Pole has made significant progress in its efforts to make portable inhaled Nitric Oxide (iNO) available in more settings and expand worldwide access to pharmaceutical iNO. I look forward to building on a culture defined by patient focus, accountability and teamwork to get Third Pole's ground- breaking iNO generation and delivery system to patient communities struggling with the most serious, life-limiting, cardio-pulmonary diseases." Athenson brings more than 25 years of experience creating profitable organisations within the pharma, life sciences, medical device, molecular diagnostics and healthcare software markets on a global basis. He has a unique blend of Fortune 15 company experience balanced with early- stage medical technology roles, as well as demonstrated success in fund raising, strategy and leveraging high impact strategic partnerships. Ashleigh Palmer, Third Pole Board member and founder of INO Therapeutics, which developed and commercialised the world's first selective pulmonary vasodilator, INOmax® nitric oxide for inhalation, acquired in 2015 for $2.3 billion, said: "Bill is the perfect leader to move Third Pole to the next level given his expertise in leading high-performance organisations transitioning from development to commercial operations. Bill's extensive experience in building cross-functional therapeutic and device development operations and partnerships, from product concept through commercial execution across U.S., Europe, and Asia, is especially relevant to the future success of Third Pole." Most recently, Athenson served as CEO of Three Lakes Partners, conducting impact funding of pioneering drug discovery, diagnostics and medical device-based technologies and collaborations focused on accelerating therapies and improving care for patients and families living with Pulmonary Fibrosis. In addition to his more than two decades of increasing leadership responsibilities at Baxter Healthcare, Athenson also served from 2002-2015 as Vice President, Global Sales, Marketing and Business Development for Nanosphere, Inc.